89Zr-radiolabeled trastuzumab imaging in orthotopic and metastatic breast tumors

Pharmaceuticals

Volumn 5, Issue 1, 2012, Pages 79-93

  Chang, Albert J ^a   DeSilva, Ravindra ^a   Jain, Sandeep ^a   Lears, Kimberley ^a   Rogers, Buck ^a   Lapi, Suzanne ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HER2; ImmunoPET; PET

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; TRASTUZUMAB ZR 89; UNCLASSIFIED DRUG; ZIRCONIUM; ZIRCONIUM 89;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CANCER MODEL; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG UPTAKE; HEART; INFERIOR CAVA VEIN; ISOTOPE LABELING; KIDNEY; LIVER; METASTASIS; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RADIOACTIVITY; TISSUE DISTRIBUTION;

EID: 84856261443     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph5010079     Document Type: Article

References (42)

1. Citri, A.; Yarden, Y. EGF-ERBB signalling: Towards the systems level. Nat. Rev. Mol. Cell Biol. 2006, 7, 505-516.
2. Slamon, D.J.; Clark, G.M.; Wong, S.G.; Levin, W.J.; Ullrich, A.; McGuire, W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177-182.
3. Slamon, D.J.; Godolphin, W.; Jones, L.A.; Holt, J.A.; Wong, S.G.; Keith, D.E.; Levin, W.J.; Stuart, S.G.; Udove, J.; Ullrich, A. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707-712.
4. Ignatiadis, M.; Desmedt, C.; Sotiriou, C.; de Azambuja, E.; Piccart, M. HER-2 as a target for breast cancer therapy. Clin. Cancer Res. 2009, 15, 1848-1852.
5. Whenham, N.; D'Hondt, V.; Piccart, M.J. HER2-positive breast cancer: From trastuzumab to innovatory anti-HER2 strategies. Clin. Breast Cancer 2008, 8, 38-49.
6. Banerjee, S.; Smith, I.E. Management of small HER2-positive breast cancers. Lancet Oncol. 2010, 11, 1193-1199.
7. Goel, S.; Chirgwin, J.; Francis, P.; Stuart-Harris, R.; Dewar, J.; Mileshkin, L.; Snyder, R.; Michael, M.; Koczwara, B. Rational use of trastuzumab in metastatic and locally advanced breast cancer: Implications of recent research. Breast 2011, 20, 101-110.
8. Guarneri, V.; Barbieri, E.; Dieci, M.V.; Piacentini, F.; Conte, P. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. Cancer Treat. Rev. 2010, 36, S62-S66.
9. Cobleigh, M.A.; Vogel, C.L.; Tripathy, D.; Robert, N.J.; Scholl, S.; Fehrenbacher, L.; Wolter, J.M.; Paton, V.; Shak, S.; Lieberman, G. et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 1999, 17, 2639-2648.
10. Dawood, S.; Broglio, K.; Buzdar, A.U.; Hortobagyi, G.N.; Giordano, S.H. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J. Clin. Oncol. 2010, 28, 92-98.
11. Slamon, D.J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344, 783-792.
12. Esteva, F.J.; Yu, D.; Hung, M.C.; Hortobagyi, G.N. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat. Rev. Clin. Oncol. 2010, 7, 98-107.
13. Wolff, A.C.; Hammond, M.E.; Schwartz, J.N.; Hagerty, K.L.; Allred, D.C.; Cote, R.J.; Dowsett, M.; Fitzgibbons, P.L.; Hanna, W.M.; Langer, A. et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 2007, 131, 18-43.
14. Moelans, C.B.; de Weger, R.A.; van der Wall, E.; van Diest, P.J. Current technologies for HER2 testing in breast cancer. Crit. Rev. Oncol. Hematol. 2011, 80, 380-392.
15. Rasbridge, S.A.; Gillett, C.E.; Seymour, A.M.; Patel, K.; Richards, M.A.; Rubens, R.D.; Millis, R.R. The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br. J. Cancer 1994, 70, 335-341.
16. van de Ven, S.; Smit, V.T.; Dekker, T.J.; Nortier, J.W.; Kroep, J.R. Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat. Rev. 2011, 37, 422-430.
17. Guarneri, V.; Giovannelli, S.; Ficarra, G.; Bettelli, S.; Maiorana, A.; Piacentini, F.; Barbieri, E.; Dieci, M.V.; D'Amico, R.; Jovic, G. et al. Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: Impact on patient management. Oncologist 2008, 13, 838-844.
18. Solomayer, E.F.; Becker, S.; Pergola-Becker, G.; Bachmann, R.; Kramer, B.; Vogel, U.; Neubauer, H.; Wallwiener, D.; Huober, J.; Fehm, T.N. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res. Treat. 2006, 98, 179-184.
19. Zurrida, S.; Montagna, E.; Naninato, P.; Colleoni, M.; Goldhirsch, A. Receptor status (ER, PgR and HER2) discordance between primary tumor and locoregional recurrence in breast cancer. Ann. Oncol. 2011, 22, 479-480.
20. Sekido, Y.; Umemura, S.; Takekoshi, S.; Suzuki, Y.; Tokuda, Y.; Tajima, T.; Osamura, R.Y. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. Int. J. Oncol. 2003, 22, 1225-1232.
21. Lear-Kaul, K.C.; Yoon, H.R.; Kleinschmidt-DeMasters, B.K.; McGavran, L.; Singh, M. Her-2/neu status in breast cancer metastases to the central nervous system. Arch. Pathol. Lab. Med. 2003, 127, 1451-1457.
22. Niu, G.; Li, Z.; Cao, Q.; Chen, X. Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab. Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 1510-1519.
23. Milenic, D.E.; Wong, K.J.; Baidoo, K.E.; Nayak, T.K.; Regino, C.A.; Garmestani, K.; Brechbiel, M.W. Targeting HER2: A report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials. MAbs 2010, 2, 550-564.
24. Capala, J.; Bouchelouche, K. Molecular imaging of HER2-positive breast cancer: A step toward an individualized 'image and treat' strategy. Curr. Opin. Oncol. 2010, 22, 559-566.
25. 89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft. Eur. J. Cancer 2010, 46, 678-684.
26. Wong, J.Y.; Raubitschek, A.; Yamauchi, D.; Williams, L.E.; Wu, A.M.; Yazaki, P.; Shively, J.E.; Colcher, D.; Somlo, G. A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. Cancer Biother. Radiopharm. 2010, 25, 387-394.
27. McCabe, K.E.; Wu, A.M. Positive progress in immunoPET-Not just a coincidence. Cancer Biother. Radiopharm. 2010, 25, 253-261.
28. Dijkers, E.C.; Oude Munnink, T.H.; Kosterink, J.G.; Brouwers, A.H.; Jager, P.L.; de Jong, J.R.; van Dongen, G.A.; Schroder, C.P.; Lub-de Hooge, M.N.; de Vries, E.G. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther. 2010, 87, 586-592.
29. 89Zr-labeled cG250-F(ab')2 in head and neck tumors. J. Nucl. Med. 2010, 51, 1076-1083.
30. 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J. Nucl. Med. 2009, 50, 1828-1836.
31. 89Zr-labeled cetuximab uptake assessed with PET. J. Nucl. Med. 2009, 50, 123-131.
32. Nagengast, W.B.; de Vries, E.G.; Hospers, G.A.; Mulder, N.H.; de Jong, J.R.; Hollema, H.; Brouwers, A.H.; van Dongen, G.A.; Perk, L.R.; Lub-de Hooge, M.N. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J. Nucl. Med. 2007, 48, 1313-1319.
33. 89Zr-labeled monoclonal antibodies. J. Nucl. Med. 2003, 44, 1271-1281.
34. Perk, L.R.; Vosjan, M.J.; Visser, G.W.; Budde, M.; Jurek, P.; Kiefer, G.E.; Van Dongen, G.A. p-Isothiocyanatobenzyl-desferrioxamine: A new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 250-259.
35. Vosjan, M.J.; Perk, L.R.; Visser, G.W.; Budde, M.; Jurek, P.; Kiefer, G.E.; van Dongen, G.A. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat. Protoc. 2010, 5, 739-743.
36. Holland, J.P.; Sheh, Y.; Lewis, J.S. Standardized methods for the production of high specific-activity zirconium-89. Nucl. Med. Biol. 2009, 36, 729-739.
37. Lindmo, T.; Boven, E.; Cuttitta, F.; Fedorko, J.; Bunn, P.A., Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods 1984, 72, 77-89.
38. Chanda, D.; Isayeva, T.; Kumar, S.; Siegal, G.P.; Szafran, A.A.; Zinn, K.R.; Reddy, V.V.; Ponnazhagan, S. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. Mol. Ther. 2008, 16, 871-878.
39. Holland, J.P.; Caldas-Lopes, E.; Divilov, V.; Longo, V.A.; Taldone, T.; Zatorska, D.; Chiosis, G.; Lewis, J.S. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS One 2010, 5, e8859.
40. 89Zr-trastuzumab for HER2/neu immunoPET imaging. J. Nucl. Med. 2009, 50, 974-981.
41. di Cosimo, S.; Baselga, J. Management of breast cancer with targeted agents: Importance of heterogeneity. [corrected]. Nat. Rev. Clin. Oncol. 2010, 7, 139-147.
42. Bartlett, A.I.; Starcyznski, J.; Robson, T.; Maclellan, A.; Campbell, F.M.; van de Velde, C.J.; Hasenburg, A.; Markopoulos, C.; Seynaeve, C.; Rea, D. et al. Heterogeneous HER2 gene amplification: Impact on patient outcome and a clinically relevant definition. Am. J. Clin. Pathol. 2011, 136, 266-274.